Adult: Monotherapy or in combination w/ MTX or other DMARDs in patients w/ moderate to severe active RA. Monotherapy or in combination w/ DMARDs in patients w/ active psoriatic arthritis. Active ankylosing spondylitis (AS). Non-radiographic axial spondyloarthritis (nr-axSpA) in patients w/ inadequate response to or are intolerant to NSAIDs. Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic- or phototherapy & when other systemic therapies are medically less appropriate. Moderate to severe active Crohn's disease in patients w/ inadequate response to conventional therapy, or who have lost response to or are infliximab-intolerant. Moderate to severe active ulcerative colitis in patients w/ inadequate response to conventional therapy including corticosteroids &/or 6-mercaptopurine or azathioprine, or who are intolerant to, or have medical CI for such therapies. Active moderate to severe hidradenitis suppurativa (HS) in patients w/ inadequate response to conventional systemic HS therapy. Non-infectious intermediate, posterior & panuveitis in patients w/ inadequate response to corticosteroids, in need of corticosteroid-sparing or in whom corticosteroids is inappropriate. Ped: Monotherapy or in combination w/ MTX for active polyarticular juvenile idiopathic arthritis (pJIA) in patients >2 yr w/ inadequate response to ≥1 DMARDs. Active enthesitis-related arthritis in patients ≥6 yr w/ inadequate response to or who are intolerant of conventional therapy. Moderate to severe active Crohn's disease in ped patients 6-17 yr w/ inadequate response to conventional therapy eg, primary nutrition therapy, corticosteroids &/or immunomodulator, or who are intolerant to or have CI for such therapies. Severe chronic plaque psoriasis in childn & adolescents from 4 yr w/ inadequate response to or are inappropriate candidates for topical- & phototherapy. Chronic non-infectious anterior uveitis in patients from 2 yr w/ inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. Active moderate to severe HS in adolescents from 12 yr w/ inadequate response to conventional systemic HS therapy.
Sign Out
